Management of psychiatric comorbidity in anorexia nervosa and bulimia nervosa.

Abstract:

:The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse. The most important principle of treating comorbidity in these conditions is the recognition of the effect of starvation and unstable eating on both the diagnosis and response to treatment of the comorbidity. This article reviews the identification of the most common areas of comorbidity and describes treatment approaches for these conditions. When it occurs, clinicians should treat comorbidity in patients with eating disorders in the usual fashion, but must remain aware that the disturbed eating itself will negatively affect response to treatment.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Woodside BD,Staab R

doi

10.2165/00023210-200620080-00004

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

655-63

issue

8

eissn

1172-7047

issn

1179-1934

pii

2084

journal_volume

20

pub_type

杂志文章,评审
  • Pharmacological interventions for the treatment of smokeless tobacco use.

    abstract::Smokeless tobacco (SLT) is used in a variety of forms throughout the world. Long-term SLT use is associated with adverse health consequences. Effective pharmacotherapies are needed to treat SLT users who want to achieve tobacco abstinence. In the current review, we discuss the pharmacological interventions identified ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11598450-000000000-00000

    authors: Ebbert JO,Fagerstrom K

    更新日期:2012-01-01 00:00:00

  • Role of the melatonin system in the control of sleep: therapeutic implications.

    abstract::The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721120-00004

    authors: Pandi-Perumal SR,Srinivasan V,Spence DW,Cardinali DP

    更新日期:2007-01-01 00:00:00

  • Cognitive effects of statin medications.

    abstract::The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Admi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0147-5

    authors: Kelley BJ,Glasser S

    更新日期:2014-05-01 00:00:00

  • Pregabalin: as adjunctive treatment of partial seizures.

    abstract::Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel alpha(2)-delta proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmit...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519030-00007

    authors: Warner G,Figgitt DP

    更新日期:2005-01-01 00:00:00

  • Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

    abstract::NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...

    journal_title:CNS drugs

    pub_type: 已发布勘误

    doi:10.1007/s40263-018-0595-4

    authors: Papadopoulos D,Mitsikostas DD

    更新日期:2019-01-01 00:00:00

  • Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

    abstract:OBJECTIVE:To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200721010-00006

    authors: Dodick DW,Sandrini G,Williams P

    更新日期:2007-01-01 00:00:00

  • Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.

    abstract::Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0123-5

    authors: Hoy SM

    更新日期:2013-12-01 00:00:00

  • Hypnosedative-induced complex behaviours : incidence, mechanisms and management.

    abstract::A number of news items and case reports describing complex behaviours (e.g. sleep driving, sleep cooking, sleep eating, sleep conversations, sleep sex) associated with the use of hypnosedative medications have recently received considerable attention. Regulatory agencies examining these reports have subsequently issue...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/0023210-200822120-00005

    authors: Dolder CR,Nelson MH

    更新日期:2008-01-01 00:00:00

  • Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

    abstract::Biopharmaceuticals can induce antibodies, which interact with and neutralize the therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In the treatment of multiple sclerosis, NAbs against interferon (IFN)-beta and natalizumab have been recognized. The prevalence of NAbs against diff...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923050-00003

    authors: Deisenhammer F

    更新日期:2009-01-01 00:00:00

  • Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion.

    abstract:INTRODUCTION:Valproic acid is a versatile antiepileptic drug that is often used in the acute care setting. Intravenous valproic acid lends itself well to a continuous infusion as it exhibits a relatively short half-life. We evaluated the pharmacokinetics and clinical efficacy of continuous infusion valproic acid in hos...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0304-5

    authors: Cook AM,Zafar MS,Mathias S,Stewart AM,Albuja AC,Bensalem-Owen M,Kapoor S,Baumann RJ

    更新日期:2016-01-01 00:00:00

  • Correction to: Propofol: A Review of its Role in Pediatric Anesthesia and Sedation.

    abstract::The original article can be found online. ...

    journal_title:CNS drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40263-018-0561-1

    authors: Chidambaran V,Costandi A,D'Mello A

    更新日期:2018-09-01 00:00:00

  • Social anxiety disorder : current treatment recommendations.

    abstract::Social anxiety disorder (SAD) is a prevalent and disabling disorder associated with significant co-morbidity. An increased awareness of SAD over the past two decades has given impetus to advances in the pharmacotherapeutic and psychotherapeutic treatment options for this disorder. On the basis of consistent data from ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519050-00002

    authors: Muller JE,Koen L,Seedat S,Stein DJ

    更新日期:2005-01-01 00:00:00

  • Therapeutic options for treatment-resistant depression.

    abstract::Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11530280-000000000-00000

    authors: Shelton RC,Osuntokun O,Heinloth AN,Corya SA

    更新日期:2010-02-01 00:00:00

  • Blonanserin: a review of its use in the management of schizophrenia.

    abstract::Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11202620-000000000-00000

    authors: Deeks ED,Keating GM

    更新日期:2010-01-01 00:00:00

  • Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.

    abstract:BACKGROUND:Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00700-0

    authors: Naismith RT,Wundes A,Ziemssen T,Jasinska E,Freedman MS,Lembo AJ,Selmaj K,Bidollari I,Chen H,Hanna J,Leigh-Pemberton R,Lopez-Bresnahan M,Lyons J,Miller C,Rezendes D,Wolinsky JS,EVOLVE-MS-2 Study Group.

    更新日期:2020-02-01 00:00:00

  • Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study.

    abstract:PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0229-z

    authors: Verrotti A,Parisi P,Agostinelli S,Loiacono G,Marra F,Coppola G,Pisani LR,Gorgone G,Striano P,Pisani F,Belcastro V

    更新日期:2015-02-01 00:00:00

  • Sodium Channel Blockers in the Treatment of Epilepsy.

    abstract::Sodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic-clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic dr...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0441-0

    authors: Brodie MJ

    更新日期:2017-07-01 00:00:00

  • Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases.

    abstract::Ursolic acid is a pentacyclic triterpenoid found in several plants. Despite its initial use as a pharmacologically inactive emulsifier in pharmaceutical, cosmetic and food industries, several biological activities have been reported for this compound so far, including anti-tumoural, anti-diabetic, cardioprotective and...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0474-4

    authors: Ramos-Hryb AB,Pazini FL,Kaster MP,Rodrigues ALS

    更新日期:2017-12-01 00:00:00

  • Treatment Strategies for Dravet Syndrome.

    abstract::Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0511-y

    authors: Knupp KG,Wirrell EC

    更新日期:2018-04-01 00:00:00

  • Atypical depression: a comprehensive review.

    abstract::Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in hormonal responses, brain ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11310990-000000000-00000

    authors: Pae CU,Tharwani H,Marks DM,Masand PS,Patkar AA

    更新日期:2009-12-01 00:00:00

  • Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

    abstract::The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115110-00004

    authors: Lacour M,Sterkers O

    更新日期:2001-01-01 00:00:00

  • Female hypoactive sexual desire disorder: epidemiology, diagnosis and treatment.

    abstract::Female hypoactive sexual desire disorder (HSDD) may occur in up to one-third of adult women in the US. The essential feature of female HSDD is a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The evaluation of female HSDD generally requ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216110-00003

    authors: Warnock JJ

    更新日期:2002-01-01 00:00:00

  • Methylene Blue in the Treatment of Neuropsychiatric Disorders.

    abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00641-3

    authors: Alda M

    更新日期:2019-08-01 00:00:00

  • Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.

    abstract:BACKGROUND:Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11588400-000000000-00000

    authors: Tobinick E

    更新日期:2011-02-01 00:00:00

  • Insomnia in patients with depression: some pathophysiological and treatment considerations.

    abstract::The almost ubiquitous sleep disturbances in patients with depression commonly, but not always, subside with the remission of depression. Evidence linking insomnia with the risk of relapses in recurrent depression, as well as suicide, makes optimization of the treatment of insomnia associated with depression a priority...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923040-00004

    authors: Jindal RD

    更新日期:2009-01-01 00:00:00

  • The new generation of GABA enhancers. Potential in the treatment of epilepsy.

    abstract::gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115050-00001

    authors: Czuczwar SJ,Patsalos PN

    更新日期:2001-01-01 00:00:00

  • The glutamatergic system and Alzheimer's disease: therapeutic implications.

    abstract::Alzheimer's disease affects nearly 5 million Americans currently and, as a result of the baby boomer cohort, is predicted to affect 14 million Americans and 22 million persons totally worldwide in just a few decades. Alzheimer's disease is present in nearly half of individuals aged 85 years. The main symptom of Alzhei...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317090-00004

    authors: Butterfield DA,Pocernich CB

    更新日期:2003-01-01 00:00:00

  • Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.

    abstract:BACKGROUND:Few studies examine predictors of seizures in medically treated patients with epilepsy receiving antiepileptic monotherapy using a large patient population. OBJECTIVE:Our objective was to identify clinical, medication, and demographic factors associated with seizure recurrence in medically treated patients ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-014-0191-1

    authors: Shcherbakova N,Rascati K,Brown C,Lawson K,Novak S,Richards KM,Yoder L

    更新日期:2014-11-01 00:00:00

  • Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

    abstract::The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0301-8

    authors: Calsolaro V,Edison P

    更新日期:2015-12-01 00:00:00

  • Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses.

    abstract::The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by mutations in at least 13 different genes and primarily affect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00620-8

    authors: Kohlschütter A,Schulz A,Bartsch U,Storch S

    更新日期:2019-04-01 00:00:00